<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02570087</url>
  </required_header>
  <id_info>
    <org_study_id>CTOHFrEF</org_study_id>
    <nct_id>NCT02570087</nct_id>
  </id_info>
  <brief_title>Benefits of CTO-PCI in Selected Cases With HFrEF (CTOHFrEF)</brief_title>
  <acronym>CTOHFrEF</acronym>
  <official_title>Benefits of Chronic Total Coronary Occlusion Percutaneous Intervention in Patients With Chronic Heart Failure and Reduced Ejection Fraction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators studied the effect of CTO-PCI on left ventricular function and clinical&#xD;
      parameters in patients with HFrEF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational studies have shown that chronic total coronary occlusion percutaneous&#xD;
      intervention (CTO-PCI) improves angina, left ventricular ejection fraction (LVEF), and&#xD;
      survival. None of these studies aimed to assess the benefits in populations with heart&#xD;
      failure with reduced ejection fraction (HFrEF). The investigators studied the effect of&#xD;
      CTO-PCI on left ventricular function and clinical parameters in patients with HFrEF.&#xD;
&#xD;
      Using cardiac magnetic resonance (CMR), the investigators studied 29 patients with HFrEF and&#xD;
      evidence of viability and/or ischemia in the territory supplied by an occluded vessel who&#xD;
      were successfully treated with CTO-PCI. Non-CTO PCI was also performed in patients with&#xD;
      multi-vessel disease, . Imaging parameters, clinical status, and brain natriuretic peptide&#xD;
      (BNP) levels were evaluated before and six months after CTO-PCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction (%)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate changes in left ventricular function by cardiac magnetic resonance imaging 6 months after CTO PCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NYHA functional class (I-V)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate changes in NYHA functional class 6 months after CTO PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial ischemia</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate changes in number of segments with induced ischemia by cardiac magnetic resonance imaging 6 months after CTO PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Natriuretic Peptide (pg/ml)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate changes in brain natriuretic peptide 6 months after CTO PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of in-hospital CTO PCI major adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Safety evaluation of CTO PCI in patients with HFrEF (periprocedural mortality, periprocedural STEMI or need for urgent myocardial revascularization surgery)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Chronic Total Occlusion Vessel</condition>
  <arm_group>
    <arm_group_label>Successful CTO PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Successful chronic total coronary occlusion percutaneous intervention (CTO-PCI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unsuccessful CTO PCI</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Unsuccessful chronic total coronary occlusion percutaneous intervention (CTO-PCI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chronic total coronary occlusion percutaneous intervention</intervention_name>
    <description>Percutaneous intervention of chronic total coronary occlusion with stent implantation</description>
    <arm_group_label>Successful CTO PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least one chronic total coronary occlusion&#xD;
&#xD;
          -  LVEF ≤40% by CMR&#xD;
&#xD;
          -  Evidence of myocardial viability and/or ischemia in at least two contiguous segments&#xD;
             subtended by the occluded vessel.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of childbearing age or pregnant&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Admission to hospital within the previous 90 days due to decompensated heart failure,&#xD;
             myocardial infarction or unstable angina.&#xD;
&#xD;
          -  Severe valvulopathy&#xD;
&#xD;
          -  Pacemaker or implantable cardioverter defibrillator&#xD;
&#xD;
          -  Indication for coronary artery bypass surgery&#xD;
&#xD;
          -  Heart transplantation waiting list&#xD;
&#xD;
          -  Follow-up not feasible&#xD;
&#xD;
          -  Life expectancy shorter than 12 months.&#xD;
&#xD;
          -  Iodine contrast or gadolinium allergy&#xD;
&#xD;
          -  Aspirin or clopidogrel allergy&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  NYHA IV class&#xD;
&#xD;
          -  Liver cirrosis&#xD;
&#xD;
          -  Noncompliance with medical treatment&#xD;
&#xD;
          -  Chronic kidney disease with serum creatinine levels ≥ 2.5 mg/dl or glomerular&#xD;
             filtration rate ≤30 ml/min/1.73m2&#xD;
&#xD;
          -  Evidence of active bleeding&#xD;
&#xD;
          -  High risk of bleeding&#xD;
&#xD;
          -  CTO distal vessel not visible through collateral circulation&#xD;
&#xD;
          -  CTO distal vessel diameter &lt;2mm&#xD;
&#xD;
          -  Absence of acceptable vascular access&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>September 25, 2015</study_first_submitted>
  <study_first_submitted_qc>October 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2015</study_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Montserrat Cardona</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>Coronary ChronicTotal Occlusion</keyword>
  <keyword>Coronary Angioplasty</keyword>
  <keyword>Reduced Ejection Fraction</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

